49
Participants
Start Date
May 1, 2006
Primary Completion Date
April 15, 2011
Study Completion Date
June 20, 2016
gemcitabine hydrochloride
Given IV
imatinib mesylate
Given orally
University of Maryland Greenebaum Cancer Center, Baltimore
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Cooper Hospital/University Medical Center, Camden
Rutgers Cancer Institute of New Jersey at Hamilton, Hamilton
Mountainside Hospital, Montclair
Jersey Shore Cancer Center at Jersey Shore University Medical Center, Neptune City
Rutgers Cancer Institute of New Jersey, New Brunswick
Saint Peter's University Hospital, New Brunswick
NJ Medical School, Newark
Collaborators (1)
National Cancer Institute (NCI)
NIH
Novartis Pharmaceuticals
INDUSTRY
Rutgers Cancer Institute of New Jersey
OTHER
Rutgers, The State University of New Jersey
OTHER